NovelMed is actively pursuing investments, partnerships, or acquisition opportunities to drive the advancement of its antibody therapy pipeline. Our lead candidates have successfully completed a Phase I trial in healthy volunteers, demonstrating safety and initial efficacy. These candidates are now advancing into Phase II clinical trials targeting multiple indications, including PNH, showcasing their broad therapeutic potential. We are dedicated to forming strategic collaborations that can not only accelerate the development and commercialization of these innovative therapies but also position them to significantly enhance the quality of care for patients across various conditions.
Seeking investments, partnerships, or acquisition opportunities to advance the development of therapies for rare diseases
NovelMed Therapeutics is a biotechnology company that conducts cutting-edge research and develops therapeutics for complement-mediated rare diseases. As a company, we are driven by our commitment to patients and a shared vision to provide innovative new therapies for unmet medical needs. We are focused on developing transformative treatment options for patients suffering from orphan and non-orphan diseases. Our approach is deeply rooted in scientific excellence and collaboration, allowing us to push the boundaries of what’s possible in drug development. At NovelMed, we believe that every breakthrough brings us closer to revolutionizing the standard of care for patients around the world.
